Uterine Transposition for Fertility Preservation and Ovarian Conservation in Patients Undergoing Pelvic Radiotherapy.
Shant Apelian, Adriana Vest, Maya Yasukawa...
https://pubmed.ncbi.nlm.nih.gov/40609092/Actively Recruiting
Led by University of South Florida · Updated on 2026-06-24
26
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are evaluating the feasibility and safety of utero-ovarian transposition UOT in female patients aged 18 to 40 years who have pelvic malignancies requiring whole pelvic external radiation therapy WPXRT. This phase I trial focuses on preserving fertility and ovarian function in premenopausal women by surgically repositioning the uterus, ovaries, and fallopian tubes outside the radiation field using a novel minimally invasive approach. The study aims to assess surgical, reproductive, and quality-of-life outcomes following UOT. Participants will undergo UOT surgery to move their reproductive organs away from radiation areas, followed by WPXRT and chemotherapy if needed. After completing cancer treatments, a second surgery will restore the organs to their natural position. Intraoperative imaging with indocyanine green fluorescence and Doppler ultrasonography will be used to enhance safety. The study monitors success in organ repositioning, surgical complications, and timely cancer treatment completion. Throughout the study, participants will be closely monitored for surgical outcomes, hormonal function FSH, LH, AMH, estradiol, menstrual cycles, and quality of life, including physical, emotional, sexual, and reproductive well-being. Follow-up assessments occur at multiple intervals up to one year post-surgery to evaluate fertility preservation and uterine receptivity. The trial provides important insights for improving surgical techniques and expanding fertility preservation options for women with pelvic cancers.
CONDITIONS
Utero-ovarian Transposition in Patients With Pelvic Malignancies Undergoing Whole Pelvic Radiotherapy
B
Brittani Powell, MPH, CCRP
J
Jennifer Childress, RN, CCRP
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of South Florida
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational uterine and ovarian transposition | Standard fertility preservation methods |
|---|---|---|
| What it is | A surgical procedure relocating the uterus, ovaries and fallopian tubes outside the planned pelvic radiation field, with a second surgery restoring their position after radiotherapy | Established fertility preservation options include ovarian transposition to move ovaries out of the radiation field, and cryopreservation of eggs, embryos or ovarian tissue |
| Role in the trial | Investigational fertility‑preserving surgical technique assessed during radiotherapy | Not part of the trial; included to show current care choices |
| Primary use | To preserve both ovarian function and uterine integrity through relocation during pelvic radiotherapy | To protect ovarian function or preserve reproductive material before gonadotoxic cancer treatment |
| How it is done | Temporary surgical relocation of uterus and adnexa followed by restoration after radiotherapy | Ovaries are moved surgically out of radiation field; or eggs, embryos or ovarian tissue are collected and frozen before treatment |
| Evidence status | Effectiveness is being evaluated; evidence limited to investigational phase | Well-supported by clinical literature and practice with documented ovarian preservation and pregnancy outcomes |
| Important risks | Not yet established risk profile; surgical risks and radiation timing considerations apply | Known surgical and anesthesia risks associated with cryopreservation or transposition; ovarian transposition risks include procedure complications |
| Important limitations | Procedural feasibility and long‑term uterine function remain under investigation | Ovarian transposition protects only ovarian function—it does not shield the uterus; cryopreservation requires time and specialized facilities |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single event with hospital stay as needed
Participants undergo minimally invasive surgery to move the uterus, ovaries, and fallopian tubes outside the radiation field to protect them during cancer treatment.
1 surgical visit and inpatient stay as needed
Duration - Varies by individual treatment plan
Participants receive whole pelvic external radiation therapy and chemotherapy if indicated to treat their pelvic malignancy after recovery from surgery.
Multiple visits for radiation and chemotherapy sessions
Duration - Up to 52 weeks post-surgery
After completing cancer treatments, participants undergo surgery to return reproductive organs to their normal position. Follow-up visits assess surgical outcomes, hormonal levels, menstrual function, and quality of life.
Regular follow-up visits at 4, 8, 12, and 52 weeks
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Shant Apelian, Adriana Vest, Maya Yasukawa...
https://pubmed.ncbi.nlm.nih.gov/40609092/Reitan Ribeiro, Glauco Baiocchi, Renato Moretti-Marques...
https://pubmed.ncbi.nlm.nih.gov/37898483/Reitan Ribeiro, Juliano Camargo Rebolho, Fernanda Keiko Tsumanuma...
https://pubmed.ncbi.nlm.nih.gov/28697913/University of South Florida
Lead Sponsor